43 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AZN Astrazeneca PLC $37.56 $95.16B Downtrend
Article Searches
Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs http://www.zacks.com/stock/news/353203/pharma-stock-roundup-q4-earnings-at-mrk-lly-chmp-nod-for-several-drugs?cid=CS-ZC-FT-353203 Feb 08, 2019 - Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.
BMY vs. AZN: Which Stock Is the Better Value Option? http://www.zacks.com/stock/news/354650/bmy-vs-azn-which-stock-is-the-better-value-option?cid=CS-ZC-FT-354650 Feb 14, 2019 - BMY vs. AZN: Which Stock Is the Better Value Option?
AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales http://www.zacks.com/stock/news/354603/astrazenecas-azn-q4-earnings-beat-new-drugs-drive-sales?cid=CS-ZC-FT-354603 Feb 14, 2019 - AstraZeneca (AZN) beats earnings and sales estimates in the fourth quarter and provides encouraging outlook for 2019. Shares up.
Congress Grills Drugmakers: 5 Key Takeaways https://www.fool.com/investing/2019/02/26/congress-grills-drugmakers-5-key-takeaways.aspx?source=iedfolrf0000001 Feb 26, 2019 - Top drug companies addressed sky-high drug prices on Capitol Hill today.
Bayer (BAYRY) Q4 Earnings Beat Estimates, Revenues Up Y/Y http://www.zacks.com/stock/news/357173/bayer-bayry-q4-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-357173 Feb 27, 2019 - Bayer's (BAYRY) fourth-quarter 2018 core earnings per share of 31 cents, per American Depositary Receipt ("ADR"), beat the Zacks Consensus Estimate of 26 cents.
Mallinckrodt (MNK) Rallies as Earnings Beat Estimates in Q4 http://www.zacks.com/stock/news/357189/mallinckrodt-mnk-rallies-as-earnings-beat-estimates-in-q4?cid=CS-ZC-FT-357189 Feb 27, 2019 - Mallinckrodt (MNK) tops earnings and sales estimates in the fourth quarter leading to a gain in share price.
Sanofi's Dupixent Gets FDA Priority Status for Nasal Polyps http://www.zacks.com/stock/news/358687/sanofis-dupixent-gets-fda-priority-status-for-nasal-polyps?cid=CS-ZC-FT-358687 Mar 11, 2019 - Sanofi (SNY) and partner Regeneron's (REGN) Dupixent gets FDA's priority review status for inadequately controlled severe chronic rhinosinusitis with nasal polyps.
Here's Why Momentum Investors Will Love Astrazeneca (AZN) http://www.zacks.com/stock/news/359525/heres-why-momentum-investors-will-love-astrazeneca-azn?cid=CS-ZC-FT-359525 Mar 14, 2019 - Does Astrazeneca (AZN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Britain Headed for a Soft Brexit? 5 Picks http://www.zacks.com/stock/news/359442/is-britain-headed-for-a-soft-brexit-5-picks?cid=CS-ZC-FT-359442 Mar 14, 2019 - Following May's fresh legislative defeat, Britain could exit the EU while retaining access to its common market.
Merck's Keytruda Gets EU Approval for Difficult Lung Cancer http://www.zacks.com/stock/news/359869/mercks-keytruda-gets-eu-approval-for-difficult-lung-cancer?cid=CS-ZC-FT-359869 Mar 15, 2019 - Merck (MRK) receives approval for Keytruda's combo therapy for first-line treatment of metastatic squamous non-small cell lung cancer population in Europe.

Pages: 12345

Page 1>